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Histone deacetylases (HDACs) are epigenetic regulators that are important for the control of various pathophysiological events.
We found that HDAC inhibitors completely abolished transforming growth factor-b1 (TGF-b1)-induced apoptosis in AML-12 and
primary mouse hepatocytes. Expression of a dominant-negative mutant of HDAC1 or downregulation of HDAC1 by RNAi both
suppressed TGF-b1-induced apoptosis. In addition, overexpression of HDAC1 enhanced TGF-b1-induced apoptosis, and the
rescue of HDAC1 expression in HDAC1 RNAi cells restored the apoptotic response of cells to TGF-b1. These data indicate that
HDAC1 functions as a proapoptotic factor in TGF-b1-induced apoptosis. In contrast, downregulation of HDAC2 by RNAi
increased spontaneous apoptosis and markedly enhanced TGF-b1-induced apoptosis, suggesting that HDAC2 has a reciprocal
role in controlling cell survival. Furthermore, inhibition of extracellular signal-regulated kinase 1/2 (ERK1/2) by MEK1 inhibitor
PD98059 or expression of a kinase-dead mutant of MEK1 restored the apoptotic response to TGF-b1 in HDAC1 RNAi cells.
Strikingly, HDAC2 RNAi caused an inhibition of ERK1/2, and the spontaneous apoptosis can be abolished by reactivation of
ERK1/2. Taken together, our data demonstrate that HDAC1 and 2 reciprocally affect cell viability by differential regulation of
ERK1/2; these observations provide insight into the roles and potential mechanisms of HDAC1 and 2 in apoptosis.
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Apoptosis is a highly controlled process that has been
implicated in various physiological and pathological events.
During apoptosis, cells shrink, chromatin becomes fragmen-
ted, the nucleus becomes condensed and/or fragmented.
Disruption of the normal control of apoptosis has been linked
with various pathological events. Transforming growth factor
(TGF)-b is a pleiotropic growth factor that positively or
negatively regulates many biological events depending on
cell status, cell type and environmental context. TGF-b has
been shown to be a strong inducer of apoptosis in primary rat
hepatocytes, Hep-3B, HuH-7, FaO hepatoma cell lines and
AML-12 murine hepatocytes.
1–6 In addition, dysregulation of
TGF-b-mediated apoptosis occurs in many diseases, such as
ﬁbrosis, autoimmunity, inﬂammation and tumorigenesis.
7–9
Although tremendous progress has been made in exploring
the regulatory effects of TGF-b1-induced apoptosis, further
studies are important for a better understanding of the
underlying mechanisms.
Mitogen-activated protein kinase (MAPK) cascades are
conservedsignal-transductionpathwaysthatrespondsensitively
to diverse extracellular stimuli in mediating cell proliferation,
differentiation, migration, stress responses, inﬂammation and
apoptosis.
10 Extracellular signal-regulated kinases 1/2
(ERK1/2) are important survival factors that have been shown
to have signiﬁcant roles during TGF-b-mediated biological
events. ERK1/2 inactivation has been reported to enhance
TGF-b-induced apoptosis and the suppression of prolifera-
tion,
11–14 whereas ERK1/2 activation is involved in
TGF-b-induced suppression of apoptosis and promotion of
proliferation.




21,22 However, knowledge regarding the factors that
control ERK1/2-mediated cell viability still remains limited.
Not only do histone deacetylases (HDACs) classically
function as epigenetic regulators through histone deacetyla-
tion but they can also function on other proteins such as
transcription factors to regulate gene transcription. HDACs
control various biological events including cardiac develop-
ment, skeletogenesis, cytoskeletal dynamics and the integrity
of endothelium.
23 There are 18 mammalian HDACs, which
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www.nature.com/cddisare grouped into four classes. The class I HDACs include
HDAC1, 2, 3 and 8 and are predominantly localised in the
nucleus. HDAC1 and 2 are the two closest homologues,
sharing the highest level of sequence identity. They hetero-
dimerise and form complexes with other molecules to execute
the same functions, such as the regulation of cardiac
development.
24 HDAC1 and 2 have also been shown to have
different biological functions. During embryonic differentia-
tion, HDAC1 is required for neuronal differentiation, whereas
HDAC2 speciﬁcally inhibits astrocyte differentiation.
25 There
are also discrepancies between the reported roles of HDAC1
and 2 in apoptosis. Knockdown of HDAC1 but not 2 in U2OS
osteosarcoma cells has been shown to induce apoptosis,
26
whereas the knockdown of HDAC2 but not HDAC1 in HeLa
cells results in apoptosis.
27 However, there is no evidence
regarding the roles of HDAC1 and 2 in controlling apoptosis in
normal cells.
HDAC inhibitors are potent inducers of apoptosis in cancer
cells. They suppress tumour growth and progression, induce
the differentiation of transformed cells and inhibit tumour
angiogenesis and invasion in vivo.
28 Hence, HDAC inhibitors
havebeenconsideredaspotentialdrugsforcancertreatment.
HDAC inhibitors are also well-studied for their selectivity,
because they can induce the apoptosis of cancer cells but
possess less toxicity towards non-cancer cells.
29 Death
receptor and mitochondrial death pathways have been
shown to participate in HDAC inhibitor-induced apoptosis.
30
However, very little is known about the biological effects of
HDAC inhibitors on the viability of normal cells. In addition,
most HDAC inhibitors inhibit HDACs non-selectively, so the
roles of different HDACs cannot be identiﬁed using HDAC
inhibitors alone.
In this study, we examined the roles of HDAC inhibitors,
HDAC1 and 2, on TGF-b1-induced apoptosis in mouse
hepatocytes. We showed that HDAC inhibitors suppress
TGF-b1-induced apoptosis and demonstrated that HDAC1
and2 had oppositerolesin apoptosis.The studyrevealed that
opposing regulation of ERK1/2 contributed to the opposite
roles of HDAC1 and 2.
Results
HDAC inhibitors suppress TGF-b1-induced apoptosis in
hepatocytes. To investigate whether HDACs, which are
major epigenetic regulators, are involved in the control of cell
apoptosis, we examined the effects of three structurally
unrelated HDAC inhibitors, trichostatin A (TSA), sodium
butyrate (NaBu) and MS-275, on TGF-b1-induced apoptosis
in AML-12 hepatocytes. AML-12 cell line was established
from hepatocytes from the mouse transgenic for human
TGF-a.
31 These cells exhibit typical hepatocyte features,
such as peroxisomes and bile canalicular-like structure and
expressing high levels of serum and gap junction proteins.
31
Most importantly, AML-12 cells are as sensitive as primary
hepatocytes to the TGF-b1, and results obtained from
AML-12 cells are highly consistent with that from primary
hepatocytes. TGF-b1 treatment induces both apoptosis and
epithelial–mesenchymal transition.
32,33 As shown in Figure 1,
HDAC inhibitors inhibited TGF-b1-induced apoptosis, as
determined by FACS (Figure 1a), acridine orange/ethidium
bromide (AO/EB) staining assay (Figure 1b), caspase-3
activity (Figure 1c) and DNA fragmentation (Supplementary
Figure 1a–c). Consistently, all three HDAC inhibitors also
abolished TGF-b1-induced apoptosis in primary mouse
hepatocytes, as determined by FACS (Figure 1d), AO/EB
staining (Figure 1e) and caspase-3 activity (Figure 1f). The
above results suggest that HDACs have critical roles in
TGF-b1-induced apoptosis in hepatocytes. These results
indicate that HDAC1 may be involved in TGF-b1-induced
apoptosis in hepatocytes. Because MS-275 is a relative
HDAC1-selective inhibitor, whose IC50 value for HDAC1
34,35
is much lower than that for other HDACs, and there is an
increase in the HDAC1 but not HDAC2 activity during TGF-
b1-induced apoptosis in AML-12 (Supplementary Figure 2a)
and primary hepatocytes (Supplementary Figure 2b), the
effect of MS-275 may be linked with the inhibition of HDAC1
activity.
HDAC1 is required for TGF-b1-induced apoptosis. Next
we investigated the roles of HDAC1 in TGF-b1-induced
apoptosis. We constructed dominant-negative c-myc-tagged
HDAC1 (DN-HDAC1) plasmids by substituting a conserved
histidine (histidine 141) in the catalytic domain with an
alanine.
36,37 Stably transfected cell clones were obtained by
transfection and were examined by immunoblotting
(Supplementary Figure 3a). The results show that TGF-b1-
induced apoptosis was completely suppressed in
DN-HDAC1 cells, as detected by FACS (Figure 2a) and
AO/EB staining (Figure 2b). To conﬁrm the role of HDAC1,
GFP-tagged wild-type HDAC1 or GFP empty vector plasmid
was transfected into AML-12 cells and stable clones were
selected by detecting GFP: The HDAC1–GFP fusion proteins
were exclusively localised in the nucleus, compared with the
diffuse distribution pattern of soluble GFP (Supplementary
Figure 3b). Both GFP and HDAC1–GFP can also be
detected by immunoblotting with GFP antibody (Supple-
mentary Figure 3c). Compared with overexpression of GFP
alone, overexpression of HDAC1–GFP signiﬁcantly increased
TGF-b1-induced apoptosis (Figure 2c). To further conﬁrm the
above results, we constructed two HDAC1 RNAi plasmids with
different target sequences (iHDAC1-S1 and -S2). After
transfection, stable cell clones were selected (Supplementary
Figure 3d). As determined by FACS, TGF-b1-induced
apoptosis was signiﬁcantly decreased in iHDAC1 cells
(Figure 2d). The inhibition of TGF-b1-induced apoptosis by
HDAC1 RNAi was also identiﬁed by DNA fragmentation
(Figure 2e) and AO/EB staining (Figure 2f) assays. In
addition, reintroduction of RNAi-resistant human GFP-tagged
HDAC1 back into iHDAC1 cells restored the TGF-b1-induced
apoptotic response (Figure 2g). These data demonstrate that
HDAC1 is required for TGF-b1-induced apoptosis in AML12
mouse heaptocytes.
HDAC2 is required for survival of AML-12
hepatocytes. To study the role of HDAC2 in TGF-b1-
induced apoptosis, HDAC2 RNAi plasmid (iHDAC2) was
constructed and transfected into AML-12 cells. Several
stable cell clones were selected (Supplementary
Figure 3d). Surprisingly, downregulation of HDAC2 by
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Cell Death and DiseaseHDAC2 RNAi caused spontaneous cell apoptosis, as
determined by FACS (Figure 3a), DNA fragmentation
(Figure 3b) and AO/EB staining (Figure 3c). In addition,
downregulation of HDAC2 signiﬁcantly increased the
apoptotic response of cells to TGF-b1 treatment (Figure
3d–f). These results indicate that in contrast to HDAC1,
HDAC2 has important part in the survival of AML-12
hepatocytes.
HDAC inhibitors abolish TGF-b1-induced inhibition of
ERK1/2 to suppress apoptosis. ERK1/2 is a well-known
survival factor and its inactivation has been recently shown to
increase the TGF-b1-induced apoptosis.
12 TGF-b1 treatment
inhibited ERK1/2 as shown by a decrease in the levels of
phosphorylated ERK1/2 (p-ERK1/2) in AML-12 cells and
primary hepatocytes (Figure 4a). Interestingly, TGF-b1 did
not inhibit ERK1/2 in MDCK (Madin–Darby canine kidney),
3T3-L1 and A549 cells (Supplementary Figure 4a), which
corresponds to its inability to induce apoptosis in these cells
(Supplementary Figure 4b). Thus, it suggests that inhibition
of p-ERK1/2 contributed to TGF-b1-induced apoptosis.
Moreover, TSA treatment activated ERK1/2 in AML-12 and
primary hepatocytes in time- and dose-dependent manners
(Figure 4b). Similar effect of NaBu and MS-275 was also
observed in AML-12 cells (Supplementary Figure 5a and b).
Consistent with these observations, TSA treatment partially
but signiﬁcantly reduced TGF-b1-induced inhibition of
ERK1/2 levels (Figure 4c). In the presence of PD98059, an
inhibitor of mitogen-activated protein kinase kinase 1
(MAPKK1, MEK1), the basal level of activated ERK1/2 was
signiﬁcantly reduced, and more pronounced decrease was
observed in the presence of both PD98059 and TGF-b1
Figure 1 HDAC inhibitors block TGF-b1-induced apoptosis. AML-12 cells and primary mouse hepatocytes were treated with TGF-b1 in the presence of the
HDAC inhibitors TSA, MS-275 or NaBu. The TGF-b1 concentration and time for treatment were 5ng/ml and 48h, unless otherwise indicated. The effects of inhibitors on
TGF-b1-inducedapoptosisinAML-12cellswereexaminedbyFACS(a),AO/EBstaining(b)andcaspase-3activity(c).TheeffectsofinhibitorsonTGF-b1-inducedapoptosis
in primary mouse hepatocytes were examined by FACS (d), AO/EB staining (e) and caspase-3 activity (f). Data are presented as means±S.D. from at least three
independent experiments
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Cell Death and Disease(Figure 4d). Correspondingly, much stronger apoptosis was
induced by TGF-b1 and PD98059 used together (Figure 4e).
However, because TSA can fundamentally induce the
ERK1/2 activation even in the presence of both PD98059
and TGF-b1, apoptosis induced by TGF-b1 and PD98059
used together was still markedly reduced by TSA in AML-12
and primary mouse hepatocytes (Figure 4e). These
results suggest that ERK1/2 activation is required for
HDAC inhibitor-mediated suppression of TGF-b1-induced
apoptosis in hepatocytes.
HDAC1 regulates apoptosis by inhibiting ERK1/2
phosphorylation. To determine whether the regulation of
ERK1/2 is related to the role of HDAC1 in TGF-b1-mediated
apoptosis, we examined p-ERK1/2 levels in HDAC1 small
interfering RNA-transfected cells. In iHDAC1 cells, as
compared with empty vector-transfected cells, TGF-b1
treatment cannot inhibit the ERK1/2 (Figure 5a).
Furthermore, inhibition of ERK1/2 by PD98059 restored the
apoptotic response of iHDAC1 cells to TGF-b1 stimulation
(Figure 5b), suggesting further that HDAC1 mediates
TGF-b1-induced apoptosis by inactivating ERK1/2. To conﬁrm
these results, AML-12 cells were transfected with the kinase-
dead form (K97A) of MEK1 (KD-MEK1). As a result, the
p-ERK1/2 levels in cells stably transfected with the HA-
tagged KD-MEK1 were signiﬁcantly reduced (Supplementary
Figure 6a) and the apoptotic response of cells to TGF-b1 was
enhanced (Supplementary Figure 6b). Interestingly, TSA
Figure 2 HDAC1 is required for TGF-b1-induced apoptosis. TGF-b1-induced apoptosis in DN-HDAC1 cells was examined by FACS (a) and AO/EB staining assays (b).
TGF-b1-induced apoptosis in GFP empty vector- and GFP-HDAC1-transfected cells (c), and in iHDAC1 cells was examined by FACS (d). Apoptosis in iHDAC1-S1-1# and
iHDAC1-S2-1# clones in response to TGF-b1 was examined by AO/EB staining (e) and DNA fragmentation assay (f). iHDAC1-S1-1# cell clone was transfected with
GFP-tagged HDAC1 or GFP vector. GFP staining and TGF-b1-induced cell apoptosis were determined by FACS (g). Values represent means±S.D. of at least three
independent experiments
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Cell Death and Diseasetreatment restored p-ERK1/2 to background levels
(Supplementary Figure 6c) and also reduced TGF-b-
induced apoptosis in KD-MEK1 cells (Supplementary
Figure 6d). In addition, overexpression of GFP-tagged
KD-MEK1 in iHDAC1 cells (Figure 5c) restored the apoptotic
response of these cells to TGF-b1 (Figure 5d). These results
further support that p-ERK1/2 has a critical role in HDAC1-
mediated TGF-b-induced apoptosis in AML-12 mouse
hepatocytes.
HDAC2 increases cell viability through activation of
ERK1/2. Because HDAC2 downregulation increased
apoptotic response to TGF-b1 (Figure 3) and caused
signiﬁcant spontaneous apoptosis (Figure 3), HDAC2
appeared important for the survival of AML-12 hepatocytes.
Indeed, ERK1/2 were signiﬁcantly inhibited in iHDAC2 cells
compared with control and iHDAC1 cells (Figure 6a).
Treatment of cells with epithelial growth factor (EGF),
which activated ERK1/2 in iHDAC2 cells (Figure 6b),
reduced the spontaneous apoptosis (Figure 6c), indicating
that ERK1/2 inhibition contributed at least in part the
spontaneous apoptosis in iHDAC2 cells. In addition, TSA
treatment also restored the levels of activated ERK1/2 levels
in iHDAC2 cells (Figure 6d) and suppressed spontaneous
apoptosis (Figure 6e). Inhibition of HDAC1 by MS-275 also
activated ERK1/2 (Figure 6f) and inhibited apoptosis in
iHDAC2 cells (Figure 6g), suggesting that HDAC1 functions
as a proapoptotic factor by inhibiting ERK1/2 during
spontaneous apoptosis in HDAC2-deﬁcient cells.
Discussion
HDAC inhibitors have been widely used to investigate the
roles and involvement of HDACs in various biological events.
In this study, we showed that HDAC inhibitors powerfully
suppress TGF-b1-induced apoptosis in mouse hepatocytes.
Figure 3 HDAC2is importantfor cellsurvival.The emptyvector- andiHDAC2-transfectedAML-12 cellswere culturedfor the indicatedtimes.Spontaneous cell apoptosis
was determined by FACS (a), DNAfragmentation(b) and AO/EBstaining (c). Theempty vectorand iHDAC2cellswere treatedwith TGF-b1 for 48h, and thenapoptosiswas
examined by FACS (d), DNA fragmentation (e) and AO/EB staining (f). Data are presented as means±S.D. from at least three independent experiments
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Cell Death and DiseaseThis suppression of TGF-b1-induced apoptosis is a new
functionofHDACinhibitorsthathasnotbeeninvestigatedand
demonstrated in previous studies. In addition, our results
demonstrate that three different HDAC inhibitors activate
ERK1/2 to suppress TGF-b1-induced apoptosis. Our results
are consistent with the previous reports that the HDAC
inhibitor valproic acid can activate ERK1/2, resulting in
suppression of serum starvation-induced apoptosis in human
umbilical vein endothelial cells.
38 Another HDAC inhibitor,
apicidin, was also shown to activate ERK1/2.
39 All of these
HDAC inhibitors are structurally unrelated: TSA is a hydro-
xamicacidcompound,NaBuandvalproicacidareshort-chain
fatty acids, whereas MS-275 is a benzamide and apicidin is a
cyclic tetrapeptide.
28 This indicates that activation of ERK1/2
is a common event induced by HDAC inhibitors and suggests
that modulation of ERK1/2 activity is an important function
of HDACs. By immunoﬂuorescence staining and immune
blotting, we found that HDAC inhibitors have no effect on the
subcellular localisation and the expression levels of HDACs,
suggesting that the regulation of subcellular localisation and
Figure 4 HDAC inhibitorsabolish TGF-b1-mediatedinactivationof ERK1/2to suppress the apoptosisinAML-12 (left panels)and primaryhepatocytes(right panels). The
effectsofTGF-b1onp-ERK1/2levelswereexaminedbyimmunoblotting(a).TSA-mediatedactivationofERK1/2wasexaminedbyimmunoblotting(b).Thecellsweretreated
with TSA (20ng/ml) for the times indicated, in the presence or absence of TGF-b1 or PD98059 (20mM). The p-ERK1/2 levels were determined by immunoblotting (c and d)
and cell apoptosis were determined by FACS in AML-12 cells (e, left panel) and by caspase-3 activity in primary hepatocytes (e, right panel). Data are presented as
means±S.D. from at least three independent experiments
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Cell Death and Diseasethe expression of HDACs are not involved in the antiapoptotic
function of HDAC inhibitors (data not shown).
Further study revealed that HDAC1 serves as a proapo-
ptotic factor and HDAC2 serves as an antiapoptotic factor
during TGF-b1-induced apoptosis in AML-12 hepatocytes.
These ﬁndings suggest that HDAC1 and 2 possess reciprocal
functions in the TGF-b signalling pathway during apoptosis.
Roles of HDACs in TGF-b-mediated biological events have
begun to emerge in the past several years. It has been
recently reported that HDAC2 functions as a key regulator for
TGF-b1-induced renal injury.
40 HDAC4 reportedly acts as a
regulator of TGF-b1-induced myoﬁbroblastic differentiation.
41
HDAC6 has been shown to be required for TGF-b1-induced
epithelial–mesenchymal transition.
42 HDAC4 and 5 were
shown to be recruited by Smad3 to repress the transcription
of Runx2 during TGF-b1-mediated inhibition of osteoblast
differentiation.
43 To the best of our knowledge, it is not
known whether HDACs are involved in the regulation of
TGF-b-mediated apoptosis. This study provides the ﬁrst
insight into the roles and the potential mechanisms of HDAC1
and 2 in TGF-b1-induced cell apoptosis.
ERK1/2 are important survival factors that promote cell
growth and inhibit apoptosis.
44,45 Our results showed that
inactivation of ERK1/2 occurs during TGF-b1-induced
apoptosis. In iHDAC1 cells that do not undergo apoptosis by
TGF-b1 treatment, p-ERK1/2 levels remained high in
response to TGF-b1, whereas in iHDAC2 cells, the basal
level of p-ERK1/2 was low, consistent with enhancement of
spontaneous and TGF-b1-induced apoptosis. These results
conﬁrm that the activation of ERK1/2 corresponds to the
viability of AML-12 hepatocytes. Ramesh et al.
46 reported that
inhibition of ERK1/2 through the activation of MAPK phos-
phataseMKP2isinvolvedintheTGF-b-inducedexpressionof
the proapoptotic protein BIM and in apoptosis. This study
demonstrates that reverse regulation of ERK1/2 is related to
opposing roles of HDAC1 and 2 in apoptosis.
Lagger et al.
47 reported that expression of HDAC2 and 3
was induced in HDAC1-deﬁcient cells but could not compen-
sate for the loss of HDAC1. In this study, the protein levels of
HDAC2 and 1 were also reciprocally upregulated in iHDAC1
and 2 cells. However, it is not clear whether such increases
have a respective role in these cells.
Because most HDAC inhibitors do not show speciﬁcity to
different HDACs, the general or net effect of HDAC inhibitors
cannotreﬂectthedistinctrolesofdifferentHDACs.Ourresults
demonstrate that HDAC1 and 2 have opposing roles in
apoptosis. However, HDAC inhibitors, which can suppress
both HDAC1 and 2, were found to inhibit apoptosis.
These results indicate that suppression of HDAC1 but not
HDAC2 can account for the inhibitory effect of HDAC
Figure 5 HDAC1 is involved in TGF-b1-induced inactivation of ERK1/2 and cell apoptosis. The effect of HDAC1 siRNA on TGF-b1-induced inactivation of ERK1/2 was
examined by immunoblotting (a). iHDAC1 cells were treated with TGF-b1 in the presence or absence of 20mM MEK1 inhibitor PD98059, and apoptosis was examined by
FACS (b). The iHDAC1-S1-1# cell clone was transiently transfected with GFP-tagged KD-MEK1 or the empty vector as examined by immunoblotting (c). The apoptotic
response to TGF-b1 in GFP-positive cells was examined by FACS (d). Data are the means±S.D. of at least three independent experiments
Regulation of cell apoptosis by HDAC1 and 2
W-W Lei et al
7
Cell Death and Diseaseinhibitors during apoptosis. In addition, we also found that
HDAC inhibitors suppressed spontaneous apoptosis in
HDAC2-deﬁcient cells, suggesting that the suppression of
apoptosis by HDAC inhibitors is independent of HDAC2.
As HDAC inhibitors has been reported to induce strong
apoptosis in cancer cells, our ﬁnding that HDAC inhibitors
can suppress apoptosis in non-cancer cells also suggests
distinct physiological contexts between cancer and non-
cancer cells.
In conclusion, our data demonstrate that HDAC1 and 2
have opposing roles during TGF-b1-induced apoptosis in
AML-12 hepatocytes: the former functions as a proapoptotic
factor, whereas the latter functions as a survival factor. These
roles are dependent on opposing effects on ERK1/2 activa-
tion. This study provides insight into the role and potential
mechanismofHDAC1and2oncellsurvivalandapoptosis.As
a summary of our study, a schematic illustration is shown in
Figure 7.
Figure 6 HDAC2 is important for maintaining ERK1/2 activation levels to keep cell survival. The basal levels of ERK1/2 activation were examined by immunoblotting in
iHDAC1-S1, iHDAC2 and empty vector-transfected cells (a). The iHDAC2 cells were cultured in the presence or absence of 100ng/ml EGF. The p-ERK1/2 levels were
examinedbyimmunoblotting10minafterthetreatment(b),andapoptosisweredeterminedbyFACS72hafterthetreatment(c).TheiHDAC2cellsweretreatedwith20ng/ml
TSA(d,e)or5mMMS-275(f,g).Thep-ERK1/2levelswereexaminedbyimmunoblotting8hafterthetreatment,apoptosisweredeterminedbyFACS72hafterthetreatment.
The data represent the means±S.D. of at least three independent experiments
Figure 7 Schematic illustration. HDAC1 and 2 execute opposing functions in
TGF-b1-induced apoptosis by reverse regulation of ERK1/2. HDAC1 and 2 function as
pro-andantiapoptoticfactors,respectively.Co-operationbetweenHDAC1and2regulates
ERK1/2 activation levels and determines the death and survival of hepatocytes
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Cell Death and DiseaseMaterials and Methods
Materials. AML-12, MDCK and A549 cells were originally purchased from
American Type Culture Collection (Manassas, VA, USA). TSA, NaBu, MS-275,
Ac-DEVD-pNA (caspase-3 substrate) and human recombinant EGF were
purchased from Sigma-Aldrich (St. Louis, MO, USA). PD98059 was from
Calbiochem (La Jolla, CA, USA). Human recombinant TGF-b1 was from
Chemicon (Rosemont, IL, USA). Antibodies for b-actin, c-myc, HA, phospho-
ERK1/2, ERK2 and HRP-conjugated secondary antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Preparing HDAC1 and 2 anti-serum. The sequence differences between
HDAC1 and 2 only exist at their C-terminals, so plasmids containing the C-terminal
sequences of HDAC1 and 2 in pGEX-4T-1 vector (GE Healthcare Bio-Sciences,
Piscataway, NJ, USA) were constructed. The primer sequences used were
as follows:50-GGAGAAGGTGGTCGCAAGAACTCTT-30 and 50-CTGCAGACCTTG
CTCAGGCC-30 for HDAC1, and 50-CTGCAGACCTTGCTCAGGCC-30 and
50-CTGCAGACCTTGCTCAGGCC-30 for HDAC2. The GST-tagged HDAC1 and 2
proteins were expressed and puriﬁed for immunisation of New Zealand white
rabbits. The serum was collected after three immunisations.
Cell culture. Cell culture and transfection reagents were from Invitrogen
(Carlsbad,CA,USA).AML-12murinehepatocyteswereculturedina1:1mixtureof
Dulbecco’s modiﬁed Eagle’s medium (DMEM) and Ham’s F12 containing 10% fetal
bovine serum and supplied with insulin (5mg/ml), transferrin (5mg/ml), selenium
(5mg/ml), dexamethasone (40ng/ml), penicillin (100units/ml) and streptomycin
(100mg/ml).MDCK,A549 and3T3-L1 cellswerecultured in DMEMcontaining10%
fetal bovine serum and supplied with penicillin (100U/ml) and streptomycin
(100mg/ml). The cells were incubated at 371C in a humidiﬁed atmosphere with 5%
CO2. Experiments were performed when cells reached 40–60% conﬂuence.
Isolation of mouse primary hepatocytes. Animal was housed in
compliance with institutional guidelines. Mouse primary hepatocytes were isolated
by a two-step in situ collagenase perfusion procedure, as described
12 with minor
modiﬁcation. Livers from 4-week-oldC57BL/6 mice (Shanghai ExperimentalAnimal
Center,ChineseAcademyofSciences)wereperfusedinsituthroughtheportalvein
with calcium- and magnesium-free Earl’s basic salt solution (EBSS) for 10min at a
rate of 5ml/min, followed by EBSS containing 0.5mg/ml of type IV collagenase for
another10minat371C.Thehepatocyteswerecollectedbycentrifugingandseeded
in DMEM/F12 medium, containing 15% FBS.
Construction of plasmids. Dominant-negative HDAC1 mutant was
generated through site mutation using PCR by changing histidine at position 141
to an alanine in the catalytic domain of the wild types and then cloning into
pcDNA3.1 plasmid vector (Invitrogen). The wild-type HDAC1 and HA-tagged
KD-MEK1 (K97A) were also subcloned into the pEGFPN3 plasmid vector
(BD Biosciences, Franklin Lakes, NJ, USA). The target sequences for HDAC1
RNAi were 50-GCAGATGCAGAGATTCAAT-30 (iHDAC1-S1) and 50-GCAGCGTC
TCTTTGAGAAC-30 (iHDAC1-S2). The target sequence for HDAC2 RNAi was 50-
GCATCAGGGTTCTGCTATG-30 (iHDAC2). These sequences were constructed
into the pPGK-super plasmid vector.
Flow cytometry analysis of apoptosis. After the indicated treatment or
transfection, cells were trypsinised and ﬁxed with 2% paraformaldehyde for 15min,
followed by incubation with 70% ethanol at 41C for over 2h. Cells were then
pelletted and washed with PBS containing 20mM EDTA. RNA was digested by
incubating samples with RNase A (1mg/ml) at 371C for at least1h. Cells were then
stained with propidium iodide (PI, ﬁnal concentration: 30mg/ml). PI- and
GFP-positive cells were detected by ﬂow cytometry (Becton Dickinson FACS
Calibur, BD Biosciences, San Jose, CA, USA). The cell apoptotic rate was
measured by the percentage of the sub-G1 DNA quantity.
AO/EB staining. Cells were stained by AO (2mg/ml) and EB (2mg/ml) (Sigma-
Aldrich), and the ﬂuorescence was visualised immediately using a ﬂuorescence
microscope. The live cells were stained uniformly green by AO, and the fragmented
or condensed nuclei of apoptotic cells were stained orange or red by EB.
DNA fragmentation assay. Cells were rinsed with PBS twice and incubated
with10mMTris-Cl,pH8.0,25mMEDTA,pH8.0,and0.25%TritonX-100onicefor
30min.Aftercentrifugationat12000 gfor15min,thesupernatantwasincubated
with RNAse at 371C for 1h and then with proteinase K at 561C overnight. The DNA
was extracted sequentially with phenol, phenol/chloroform (1:1), and chloroform.
The DNA in the aqueous phase was precipitated and then separated by 1.5%
agarose gel electrophoresis and visualised under transmitted UV light.
Preparation of cell lysates and immunoblotting. Cells were lysed in
lysis buffer containing 50mmol/l HEPES (pH 7.4), 5mmol/l EDTA, 50mmol/l NaCl,
1% Triton X-100, 50mmol/l NaF, 10mmol/l Na4P2O7 10H2O, 5mg/ml aprotinin,
5mg/ml leupeptin, 1mmol/l Na3VO4, and 1mmol/l phenylmethylsulfonyl ﬂuoride.
Proteins (30mg) were electrophoresed in SDS-polyacrylamide gels and transferred
onto nitrocellulose membranes. The membranes were subsequently blocked with
5% skimmed milk and incubated with appropriate primary and second antibodies.
Protein bands were visualised with super signal reagents.
Caspase-3 activity assay. Cells in 35-mm dishes were harvested by trypsin
digestion and then were lysed in lysis buffer (containing 50mmol/l HEPES (pH7.4),
5mmol/l CHAPS and 5mmol/l DTT) on ice for 20min. After centrifuging, 50ml
supernatant was mixed with 50ml assay buffer (containing 0.4mmol/l Ac-DEVD-
pNA, 4mmol/l EDTA and 5mmol/l DTT). Absorbance at 405nm was calculated
after the mixtures were incubated at 371C for 8h. For statistic data of several
experiments, the negative controls were set as 1.0.
HDAC activity assay. Cells in 35-mm dishes were lysed in the same lysis
buffer as immunoblotting assay. After centrifuging, the supernatant was
immunoprecipitated with 1ml of anti-serum of HDAC1 (or 2) and 20ml of slurry of
50%proteinASepharoseCL-4Bbeads(GEHealthcare,Piscataway,NJ,USA)ona
rotator at 41C overnight. The immunoprecipitated beads were washed with lysis
buffer and PBS three times, respectively. Then HDAC1 or 2 activity was examined
by HDAC assay kit from Upstate (Millipore, Billerica, MA, USA). Absorbance at
405nm was calculated and for statistic data of several experiments, the negative
controls were set as 1.0.
Celltransfection. Cellsin35-mmdishesweretransfectedwith2mgofplasmid
using the Lipofectamine transfection reagent (Invitrogen) according to the
manufacturer’s instruction. For transient transfection, expression of the indicated
plasmids was examined 48h after transfection. For selecting the stable cell clones,
G418 (800mg/ml) was added 48h after the transfection.
Confocal analysis. Cells stably transfected with GFP and HDAC1–GFP were
grown on glass slides.Whencells reachedconﬂuence,the slides werewashedwith
PBS and ﬁxed in 4% paraformaldehyde and permeabilised in 0.1% Triton X-100.
The nuclei were stained with DAPI. The ﬂuorescence was visualised using confocal
ﬂuorescence microscopy (Leica, Mannheim, Germany).
Statistical analysis. Quantitative data were expressed as means±S.D. or
S.E. for at least three independent experiments. Statistical signiﬁcance was
determined by Student’s t-test. Differences were considered signiﬁcant at Po0.05.
*Po0.05; **Po0.001.
Conﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgements. We are grateful to Dr. T Kouzarides for the plasmids of
wild-type human HDAC1 and mouse HDAC2, Dr. NG Ahn for the plasmid encoding
the kinase-dead form of human MEK1 (K97A), and Dr. Y Wang and Dr. K Liao for
the plasmids of pPGK-super vector and the 3T3-L1 cell line, respectively. We also
thankDr.H-HChen,G-WShu,JShi,X-DWang,LZhang,X-WYuanandY-NTang
for technical supports and many helpful discussions. This work was supported by
The Natural Science Foundation of China (30730023, 30721065 and 30623003),
the National Basic Research Program of China (2007CB947900) and the Shanghai
Science Committee 088014199.
1. Oberhammer FA, Pavelka M, Sharma S, Tiefenbacher R, Purchio AF, Bursch W et al.
Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming
growth factor beta 1. Proc Natl Acad Sci USA 1992; 89: 5408–5412.
Regulation of cell apoptosis by HDAC1 and 2
W-W Lei et al
9
Cell Death and Disease2. Lin JK, Chou CK. In vitro apoptosis in the human hepatoma cell line induced by
transforming growth factor beta 1. Cancer Res 1992; 52: 385–388.
3. Fan G, Ma X, Kren B, Steer C. The retinoblastoma gene product inhibits TGF-beta1
induced apoptosis in primary rat hepatocytes and human HuH-7 hepatoma cells.
Oncogene 1996; 12: 1909–1919.
4. BaylyA,RobertsR,DiveC.Suppressionoflivercellapoptosisinvitrobythenon-genotoxic
hepatocarcinogen and peroxisome proliferator nafenopin. J Cell Biol 1994; 125: 197–203.
5. Schuster N, Krieglstein K. Mechanisms of TGF-beta-mediated apoptosis. Cell Tissue Res
2002; 307: 1–14.
6. Liao JH, Chen JS, Chai MQ, Zhao S, Song JG. The involvement of p38 MAPK in
transforming growth factor beta1-induced apoptosis in murine hepatocytes. Cell Res 2001;
11: 89–94.
7. Lee CG, Kang HR, Homer RJ, Chupp G, Elias JA. Transgenic modeling of transforming
growth factor-beta(1): role of apoptosis in ﬁbrosis and alveolar remodeling. Proc Am
Thorac Soc 2006; 3: 418–423.
8. Aoki CA, Borchers AT, Li M, Flavell RA, Bowlus CL, Ansari AA et al. Transforming growth
factor beta (TGF-beta) and autoimmunity. Autoimmun Rev 2005; 4: 450–459.
9. Wrzesinski SH, Wan YY, Flavell RA. Transforming growth factor-beta and the
immune response: implications for anticancer therapy. Clin Cancer Res 2007; 13
(18 Part 1): 5262–5270.
10. Owens DM, Keyse SM. Differential regulation of MAP kinase signalling by dual-speciﬁcity
protein phosphatases. Oncogene 2007; 26: 3203.
11. Park HJ, Kim B-C, Kim SJ, Choi KS. Role of MAP kinases and their cross-talk in
TGF-beta1-induced apoptosis in FaO rat hepatoma cell line. Hepatology 2002; 35:
1360–1371.
12. Godoy P, Hengstler JG, Ilkavets I, Meyer C, Bachmann A, Mu ¨ller A et al. Extracellular
matrix modulates sensitivity of hepatocytes to ﬁbroblastoid dedifferentiation and
transforming growth factor beta-induced apoptosis. Hepatology 2009; 49: 2031–2043.
13. Dixon M, Agius L, Yeaman SJ, Day CP. Inhibition of rat hepatocyte proliferation by
transforminggrowthfactorbetaandglucagonisassociatedwithinhibitionofERK2andp70
S6 kinase. Hepatology 1999; 29: 1418–1424.
14. Giehl K, Seidel B, Gierschik P, Adler G, Menke A. TGFbeta1 represses proliferation of
pancreatic carcinoma cells which correlates with Smad4-independent inhibition of ERK
activation. Oncogene 2000; 19: 4531–4541.
15. ChinBY,PetracheI,ChoiAMK,ChoiME.Transforminggrowthfactorbeta1rescuesserum
deprivation-induced apoptosis via the mitogen-activated protein kinase (MAPK) pathway in
macrophages. J Biol Chem 1999; 274: 11362–11368.
16. Ghayor C, Rey A, Caverzasio J. Prostaglandin-dependent activation of ERK mediates cell
proliferation induced by transforming growth factor beta in mouse osteoblastic cells. Bone
2005; 36: 93–100.
17. Chen G, Khalil N. TGF-beta1 increases proliferation of airway smooth muscle cells by
phosphorylation of map kinases. Respir Res 2006; 7:2 .
18. Tian YC, Chen YC, Chang CT, Hung CC, Wu MS, Phillips A et al. Epidermal growth factor
and transforming growth factor-beta1 enhance HK-2 cell migration through a synergistic
increase of matrix metalloproteinase and sustained activation of ERK signaling pathway.
Exp Cell Res 2007; 313: 2367–2377.
19. Giehl K, Imamichi Y, Menke A. Smad4-independent TGF-beta signaling in tumor cell
migration. Cells Tissues Organs 2007; 185: 123–130.
20. Leloup L, Daury L, Maze `res G, Cottin P, Brustis J-J. Involvement of the ERK/MAP kinase
signalling pathway in milli-calpain activation and myogenic cell migration. Int J Biochem
Cell Biol 2007; 39: 1177–1189.
21. Ellenrieder V, Hendler SF, Boeck W, Seufferlein T, Menke A, Ruhland C et al.
Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal
transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated
kinase 2 activation. Cancer Res 2001; 61: 4222–4228.
22. Xie L, Law BK, Chytil A, Brown KA, Aakre M, Moses HL. Activation of the Erk pathway is
required for TGF-beta1-induced EMT in vitro. Neoplasia 2004; 6: 603–610.
23. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in
development and physiology: implications for disease and therapy. Nat Rev Genet 2009;
10: 32–42.
24. Montgomery RL, Davis CA, Potthoff MJ, Haberland M, Fielitz J, Qi X et al. Histone
deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and
contractility. Genes Dev 2007; 21: 1790–1802.
25. Humphrey GW, Wang Y-H, Hirai T, Padmanabhan R, Panchision DM, Newell LF et al.
Complementary roles for histone deacetylases 1, 2, and 3 in differentiation of pluripotent
stem cells. Differentiation 2007; 76: 348–356.
26. Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A et al. Role for
histone deacetylase1inhumantumorcellproliferation.MolCellBiol2007;27:4784–4795.
27. Huang BH, Laban M, Leung CH-W, Lee L, Lee CK, Salto-Tellez M et al. Inhibition of
histone deacetylase2increasesapoptosisandp21Cip1/WAF1 expression,independentof
histone deacetylase 1. Cell Death Differ 2005; 12: 395–404.
28. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase
inhibitors. Nat Rev Drug Discov 2006; 5: 769–784.
29. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and
more) treatments for cancer. Nat Rev Cancer 2006; 6: 38–51.
30. CarewJS,GilesFJ,NawrockiST.Histonedeacetylaseinhibitors:mechanismsofcelldeath
and promise in combination cancer therapy. Cancer Lett 2008; 269: 7–17.
31. Wu JC, Merlino G, Fausto N. Establishment and characterization of differentiated,
nontransformed hepatocyte cell lines derived from mice transgenic for transforming growth
factor alpha. Proc Natl Acad Sci USA 1994; 91: 674–678.
32. Yang Y, Pan X, Lei W, Wang J, Song J. Transforming growth factor-beta1 induces
epithelial-to-mesenchymal transition and apoptosis via a cell cycle-dependent mechanism.
Oncogene 2006; 25: 7235–7244.
33. Yang Y, Pan X, Lei W, Wang J, Shi J, Li F et al. Regulation of transforming growth factor-
beta1-induced apoptosis and epithelial-to-mesenchymal transition by protein kinase A and
signal transducers and activators of transcription 3. Cancer Res 2006; 66: 8617–8624.
34. Hu E, Dul E, Sung CM, Chen Z, Kirkpatrick R, Zhang GF et al. Identiﬁcation of novel
isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther
2003; 307: 720–728.
35. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N et al. Determination of the
class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J
2003; 409: 581–589.
36. Hassig CA, Fleischer TC, Billin AN, Schreiber SL, Ayer DE. Histone deacetylase activity is
required for full transcriptional repression by mSin3A. Cell 1997; 89: 341–347.
37. Grozinger CM, Hassig CA, Schreiber SL. Three proteins deﬁne a class of human histone
deacetylases related to yeast Hda1p. Proc Natl Acad Sci USA 1999; 96: 4868–4873.
38. Michaelis M, Suhan T, Michaelis UR, Beek K, Rothweiler F, Tausch L et al. Valproic acid
induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in
endothelial cells. Cell Death Differ 2006; 13: 446–453.
39. ParkH, ImJY,Kim J,ChoiWS,Kim HS.Effectsofapicidin, ahistone deacetylaseinhibitor,
on the regulation of apoptosis in H-ras-transformed breast epithelial cells. Int J Mol Med
2008; 21: 325–333.
40. Noh H, Oh EY, Seo JY, Yu MR, Kim YO, Ha H et al. Histone deacetylase-2 is a key
regulator of diabetes- and transforming growth factor-beta1-induced renal injury. Am J
Physiol Renal Physiol 2009; 297: F729–F739.
41. Glenissona W, Castronovoa V, Waltregny D. Histone deacetylase 4 is required for
TGFbeta1-induced myoﬁbroblastic differentiation. Biochim Biophys Acta 2007; 1773:
1572–1582.
42. Shan B, Yao TP, Nguyen HT, Zhuo Y, Levy DR, Klingsberg RC et al. Requirement of
HDAC6 for transforming growth factor-beta1-induced epithelial-mesenchymal transition.
J Biol Chem 2008; 283: 21065–21073.
43. Kang JS, Alliston T, Delston R, Derynck R. Repression of Runx2 function by
TGF-beta through recruitment of class II histone deacetylases by Smad3. EMBO J
2002; 24: 2543–2555.
44. Meloche S, Pouysse ´gur J. The ERK1/2 mitogen-activated protein kinase pathway as a
master regulator of the G1- to S-phase transition. Oncogene 2007; 26: 3227–3239.
45. Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death
Differ 2009; 16: 368–377.
46. Ramesh S, Qi X-J, Wildey GM, Robinson J, Molkentin J, Letterio J et al. TGF
beta-mediated BIM expression and apoptosis are regulated through SMAD3-dependent
expression of the MAPK phosphatase MKP2. EMBO Rep 2008; 9: 990–997.
47. Lagger G, O’Carroll D, Rembold M, Khier H, Tischler J, Weitzer G et al. Essential function
of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J
2002; 21: 2672–2681.
Cell Death and Disease is an open-access journal
published by Nature Publishing Group. This article is
licensedunderaCreativeCommonsAttribution-Noncommercial-Share
Alike 3.0 License. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-sa/3.0/
Supplementary Information accompanies the paper on Cell Death and Disease website (http://www.nature.com/cddis)
Regulation of cell apoptosis by HDAC1 and 2
W-W Lei et al
10
Cell Death and Disease